$EW

Markowitz Wayne sold $819K of EW

Markowitz Wayne (CVP, JAPAC) sold 9,628 shares of Edwards Lifesciences Corp (EW) at $85.06 ($0.82M total) on 2026-07-28.

Original reporting
SEC EDGAR · Markowitz Wayne
Published Jul 28, 2026, 11:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 28, 2026, 11:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EW
Neutral
medium confidence
Mentioned
$EW
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EWNeutralLow
01

Why it matters

This is a disclosed open-market sale by an officer, which may marginally influence sentiment but does not change company guidance, operations, or risk in the text provided.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new fundamental information in the filing excerpt.

03

What to watch

The article does not state whether the sale was part of a broader pattern, nor does it provide context on total holdings changes beyond the post-transaction share count.

Relevance 5/10Novelty 3/10Timing: Filed 2026-07-28, after-hours SEC Form 4 disclosure

Background

The article is an SEC Form 4 insider transaction disclosure for Edwards Lifesciences (EW).

Company-level read

Ticker impact

$EWNeutralMedium confidence
Context

Edwards Lifesciences insider Wayne Markowitz filed a Form 4 selling 9,628 shares at $85.06 on 2026-07-28.

Expected impact

Likely minimal price impact; any effect is short-lived and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan and a moderate dollar value, but it is not a corporate action, guidance change, or regulatory event.

Market effects

No clear sector read-through from a single insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs, so the signal may be noise.

Key entities

  • Edwards Lifesciences Corp

    Subject of the Form 4 insider transaction disclosure.

  • Markowitz Wayne

    Officer who sold 9,628 shares of EW at $85.0600/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EWMed

FDA Approves First Heart Valve to Keep Pace With Children's Growth

The FDA approved Edwards Lifesciences' Autus Size-Adjustable Valve, the first heart valve designed to expand with a child's growth, for pediatric patients with congenital pulmonary valve disease. The valve can be implanted at 13 mm and expanded to 22 mm, potentially reducing repeat open-heart surgeries. The approval was based on a pivotal trial with 62 patients, showing acceptable hemodynamic performance and no major complications at 6 months.

$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.